Directory

Jennifer Spratlin

Contact Overview Publications

Contact

Faculty of Medicine & Dentistry - Oncology Dept
Email
jls1@ualberta.ca

Overview

Area of Study / Keywords

About

Dr. Spratlin is an assistant professor at the Cross Cancer Institute, University of Alberta, in Edmonton, Alberta, Canada.  She graduated with her MD degree in 2001 with Honours in Research at the University of Alberta.  She then completed her Internal Medicine and subsequent Medical Oncology training at the University of Alberta (2004) and Cross Cancer Institute (2006), respectively, and is certified in Canada by the Royal College of Physicians and Surgeons of Canada in both specialties.  She spent two years under the mentorship of Dr. S. Gail Eckhardt at the University of Colorado at Denver gaining specialized training in developmental therapeutics/investigations new drugs (IND)/phase I clinical trials, gastrointestinal malignancies, and translational research.  In 2008, she returned to the Cross Cancer Institute where she is currently a member of both the gastrointestinal tumour group and the IND team.  She is lead in the Alberta provincial IND mandate.

Research

Phase I and II clinical trials
Gastrointestinal malignancies
Pancreatic cancer

Featured Publications

A 107 gene Nanostring assay effectively characterizes complex multiomic gastric cancer molecular classification in a translational patient-derived organoid model.

ASCO ANNUAL MEETING 2022. 2022 June;

A Phase 1b Dose Escalation Study of CD137 mAb Agonist OC-001 as Monotherapy in Patients with Advanced or Metastatic Cancer.

ESMO Annual Meeting. 2022 June;

Anaka MR, Lee M, Lim E, Ghosh S, Cheung WY and Spratlin JL. Changing rates of goals of care (GoC) designations in patients with advanced pancreatic cancer during a multifactorial advanced care planning initative: A real world evidence study. JCO Oncol Pract. 2022 Feb 2:OP2100649. Online ahead of print.

Anaka MR, Lee M, Lim E, Ghosh S, Cheung WY and Spratlin JL.

JCO Oncol Pract. 2022 Feb 2:OP2100649. . 2022 June; 18 (6):869-876 https://doi.org/10.1200/op.21.00649

BOLD-100-10 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: interim safety and efficacy.

ASCO Annual Meeting 2022. 2022 June;

A Phase 1/2 Study of Oral Chk1 Inhibitor LY2880070 in Combination with Low-Dose Gemcitabine in Patients with Advanced or Metastatic Ovarian Cancer.

ESMO Annual Meeting 2022. 2022 June;

N-myristoyltransferase inhibition with PCLX-001in hematologic cancers: pre-clinical and clinical trial findings

ESMO 2022 ANNUAL MEETING. 2022 May;

Artifical intelligence in gastric cancer diagnosis/treatment personalized survival moded built from composite molecular subtypes in 2022 gastric cancer patients.

International Gastric Cancer Congress (IGCC22-ABS-1109) Spring 2022.. 2022 April;

The Influence of Adjuvant Chemotherapy Dose Intensity on Overall Survival in Resected Colon Cancer: A Multicentered Retrospective Analysis

Breadner D, Loree JM, Cheung WY, Gipson M, Lakkunarajah S, Mulder KE, SPRATLIN JL, Kong S, Ding PQ, Gill S and Welch SA.

PanCanCC DI DMC Cancer. . 2022 April; 38 (4) doi.org/10.1200/JCO.2020.38.4_SUPPL.248

Real-world treatment patterns, clinical outcomes, and health care resources utilization in advanced unresectable hepatocellular carcinoma

O’Sullivan DE, Boyne DJ, Syed IA, Shephard C, Clouthier DL, Yoshida EM, SpratlinJL, Batra A, Rigo R, Hannouf M, Hu, XY, Jarada T, Brenner DR and Cheung WY. Real-world treatment patterns, clinical outcomes, and health care resources utilization in advanced unresectable hepatocellular carcinoma. Canadian Liver Journal doi: 10.3138/canlivj-2022-0001.

Canadian Liver Journal. 2022 March; doi: 10.3138/canlivj-2022-0001.

Novel, First-In-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma.

. Curr. Oncol. March 13, 2022, 29(3), 1939-1946; . 2022 March; https://doi.org/10.3390/curroncol29030158

Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma.

Sangha R, Davies NM, Namdar A, Chu M, Spratlin J, Beauchamp E, Berthiaume LG, Mackey JR

Curr Oncol. . 2022 March; 29 (3):1939-1946 doi: 10.3390/curroncol29030158

Changing Rates of Goals of Care Designations in Patients With Advanced Pancreatic Cancer During a Multifactorial Advanced Care Planning Initiative: A Real-World Evidence Study

Anaka MR, Lee M, Lim E, Ghosh S, Cheung WY and Spratlin JL

JCO Onc Pract. 2022 February; 18 doi: 10.1200/OP.21.00649.

. Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma.

ASCO GI Cancers Symposium.. 2022 January;

A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta

CAMO. 2021 April;

Murine gastric tissue establishes and maintains intestinal organoid viability after 48 hours of cold ischemia time in a mock-shipment simulation

CAMO. 2021 April;

Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma

Omar M Abdel-Rahman Abdelsalam, Jennifer Spratlin and Sheryl Koski

MEDICAL ONCOLOGY. 2021 February; 38 (2) 10.1007/s12032-021-01469-y

A population based restrospective study of biliary tract cancers in Alberta, Canada.

Beaulieu C, Lui A, Yusuf D,Abdelazia Z, Randolph R, Batuyong E, Ghosh S, Bather OF, Tam V and Spratlin JL

Current Oncology. 2021 January; 28 (1):417-427 10.3390/curroncol28010044

A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada

Beaulieu C, Lui A, Yusuf D,Abdelazia Z, Randolph R, Batuyong E, Ghosh S, Bather OF, Tam V and Spratlin JL.

Current Oncology. 2021 January; 28 (1):417-427 doi: 10.3390/curroncol28010044.

BOLD-100-001 (TRIO039): A Phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid tumors.

ASCO. 2021 January;

A Phase 1b Study of Oral Chk1 Inhibitor LY2880070 as Monotherapy in Patients with Advanced or Metastatic Cancer.

ASCO . 2020 December;

A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies

SITC. 2020 November;

Interluken-8-neutralizing monoclonal antibody BMS_986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti-PD-(L)1 experienced patients with advanced cancer: initial phase 1 results

SITC. 2020 November;